Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

not_yet_recruiting150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_1

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

NCT06641648
unknownphase_2

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

NCT05171309

Clinical Trials (2)

Showing 2 of 2 trials
NCT06641648Phase 1

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

Not Yet Recruiting
NCT05171309Phase 2

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2